Todas as fotos(1)

Documentos Principais

I0361000

Ipratropium bromide impurity B

Name: Ipratropium bromide impurity B
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

(1R,3r,5S,8s)-3-[[(2RS)-3-Hydroxy-2-phenylpropanoyl]oxy]-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide

Faça loginpara ver os preços organizacionais e de contrato

Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):

C₂₀H₃₀BrNO₃

Número CAS:

58073-59-9

Peso molecular:

412.36

Código UNSPSC:

41116107

NACRES:

NA.24

Produtos recomendados

Slide 1 of 10

1 of 10

Y0000276

Ipratropium impurity A

BP930

Ciprofloxacin impurity standard

X0101000

Xylometazoline impurity A

BP626

8s-Isopropyl-3β-hydroxytropanium bromide

Supelco

PHR3017

Ipratropium Bromide Related Compound A

Y0000757

(−)-Riboflavina

I0360000

Ipratropium bromide

Y0000030

Salbutamol impurity B

813068

TSKgel^® CM-5PW HPLC Column

BP1232

Ipratropium bromide Impurity D

grau

pharmaceutical primary standard

família API

ipratropium

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

temperatura de armazenamento

2-8°C

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Materiais de referência

Materiais de referência analítica para CQ farmacêutico

Padrões de farmacopeias e institutos de metrologia

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Ipratropium bromide impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto

Descrição

Preços

Palavra indicadora

Warning

Frases de perigo

H302

Declarações de precaução

P264 - P270 - P301 + P312 - P501

Classificações de perigo

Acute Tox. 4 Oral

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

The effect of bronchodilators administered via aerochamber or a nebulizer on inspiratory lung function parameters.

S K Ramlal et al.

Respiratory medicine, 107(9), 1393-1399 (2013-06-19)

In chronic obstructive pulmonary disease (COPD) the clinical efficacy of bronchodilator therapy delivered via a nebulizer versus an aerochamber on FEV1 is controversial. No studies comparing changes in inspiratory pulmonary function parameters (ILPs) using these inhaler devices are currently available.

Evaluation of lung function and deposition of aerosolized bronchodilators carried by heliox associated with positive expiratory pressure in stable asthmatics: a randomized clinical trial.

Luciana Alcoforado et al.

Respiratory medicine, 107(8), 1178-1185 (2013-05-15)

While administration of medical aerosols with heliox and positive airway pressure are both used clinically to improve aerosol delivery, few studies have differentiated their separate roles in treatment of asthmatics. The aim of this randomized, double blinded study is to

Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD.

Virginia Norris et al.

Pulmonary pharmacology & therapeutics, 26(5), 574-580 (2013-03-26)

There are few data on the bronchodilatory effects of adding short-acting bronchodilators (SABA) to maintenance, long-acting bronchodilator therapy. This study assessed the additional bronchodilation and safety of adding supratherapeutic doses of salbutamol (SALB) or ipratropium bromide (IPR) to the novel

Intranasal ipratropium bromide for the common cold.

Zaina H AlBalawi et al.

The Cochrane database of systematic reviews, 6(6), CD008231-CD008231 (2013-06-21)

The common cold is one of the most common illnesses in humans and constitutes an economic burden both in terms of productivity and expenditure for treatment. There is no proven cure for the common cold and symptomatic relief is the

Predictors of adherence to inhaled medications.

John C Huetsch et al.

Journal of general internal medicine, 28(6), 759-759 (2013-03-27)

Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica